The argument · idea-002
For use by licensed veterinarians and veterinary technicians in clinical and post-discharge settings to apply controlled sub-atmospheric pressure to open, contaminated, or free-skin-grafted distal-extremity wounds in dogs and horses, as an adjunct to standard wound management.
Chairs disagreeing in writing is the output here, not a
problem to be resolved. A blocks verdict opens an impact review; it does
not kill anything, and no department holds a veto. Killing is Stage 5 arithmetic over verified
claims. converged is not an approval either — the only approval in this repo is a
human's, at Stage 6.
flowchart TD
A14["Gross margin at the proposed…<br><small>A14 · claim 27 · unconfirmed</small>"]
A15["A fur-compatible adhesive drape can…<br><small>A15 · claim 28 · unconfirmed</small>"]
A16["The limb-conforming interface layer…<br><small>A16 · claim 29 · unconfirmed</small>"]
A20["A bench-plus-in-vivo seal-duration…<br><small>A20 · claim 46 · unconfirmed</small>"]
A3["FTO risk concentrates not in the…<br><small>A3 · claim 7 · unconfirmed</small>"]
A39["The mean pump ON-time duty cycle…<br><small>A39 · claim 65 · unconfirmed</small>"]
A4["Pet insurance penetration in the US…<br><small>A4 · claim 12 · unconfirmed</small>"]
A41["UN Manual of Tests and Criteria…<br><small>A41 · claim 67 · unconfirmed</small>"]
A42["IEC 62133-2 ('Secondary cells and…<br><small>A42 · claim 68 · unconfirmed</small>"]
A43["IEC 60601-1 is within scope for a…<br><small>A43 · claim 69 · unconfirmed</small>"]
A8["Moat lever — the defensible assets…<br><small>A8 · claim 16 · unconfirmed</small>"]
A9["Capital intensity — first revenue…<br><small>A9 · claim 18 · unconfirmed</small>"]
d_regulatory["Regulatory<br><small>conditional</small>"]
d_clinical["Clinical & Scientific<br><small>conditional</small>"]
d_market-access["Market Access<br><small>conditional</small>"]
d_technology["Technology & R&D<br><small>conditional</small>"]
d_operations-npi["Operations & NPI<br><small>conditional</small>"]
d_legal-ip["Legal & IP<br><small>conditional</small>"]
d_commercial["Commercial<br><small>conditional</small>"]
A14 --> d_operations-npi
A14 --> d_commercial
A15 --> d_technology
A15 --> d_operations-npi
A16 --> d_technology
A16 --> d_operations-npi
A20 --> d_clinical
A20 --> d_technology
A3 --> d_legal-ip
A3 --> d_commercial
A39 --> d_technology
A39 --> d_operations-npi
A4 --> d_market-access
A4 --> d_commercial
A41 --> d_technology
A41 --> d_operations-npi
A42 --> d_technology
A42 --> d_operations-npi
A43 --> d_regulatory
A43 --> d_technology
A8 --> d_legal-ip
A8 --> d_commercial
A9 --> d_operations-npi
A9 --> d_commercial
class A14,A15,A16,A20,A3,A39,A4,A41,A42,A43,A8,A9,d_regulatory,d_clinical,d_market-access,d_technology,d_operations-npi,d_legal-ip,d_commercial t2;Each chair answers cold, from its own field, without reading the others' position files. What it states is a verdict, the conditions that would change it, and the requests it raises. A condition bound to a claim is a load-bearing statement, which is why it shows up in the register below.
backs it only if its conditions hold
backs it only if its conditions hold
backs it only if its conditions hold
backs it only if its conditions hold
backs it only if its conditions hold
backs it only if its conditions hold
backs it only if its conditions hold
The opportunity is still in its original shape — no pivot has been recorded. That is not the same as being confirmed; it means no failed statement has yet forced a change of shape.
When a registered statement comes back refuted or unconfirmed, an
impact review fires. It has exactly three available outcomes and
check_loop.py refuses a record that invents a fourth. Open one for the reasoning.
both returned {"status": "unconfirmed", "source_ref": null, "detail": "EPO (European Patent Office)_OPS_KEY /
EPO_OPS_SECRET not set..."}` (Legal & IP (intellectual property)'s own connector run, 2026-09-13; an earlier pass
recorded the identical gap under the since-retired PATENTSVIEW_API_KEY name). Nothing was
looked up in either direction on either patent — this is a missing-credential gap, not a
finding about either patent's status.
abstains verdict names configuring
these credentials as "the cheapest single move" and states plainly it "would not move this
verdict off abstains on its own."
EPO_OPS_KEY/EPO_OPS_SECRET, then re-run python3 -m connectors patent US5636643 and,
once a human confirms the correct family member, US5645081. It is queued for the
Verifier's next pass rather than a cross-department research question, so no ledger request
was raised against it — it needs configuration, not research.
patent connector takes a single patent
ID and runs no landscape or assignee search, and this claim names no patent number. Legal &
IP's own corroborating check (a 510(k) landscape pull, not a patent search) found 111
clearances under product code OMP over ~10.7 years, with ongoing drape-specific filing
activity from incumbents through 2024 — a marketing-authorization record, not a patent
finding, and Legal is explicit it should not be read as one.
abstains, C3) and Commercial (REQ-0009 Does a prior-art/FTO search establish that…, which
asks whether this claim blocks Route A's moat or Route B's licensing thesis).
patent connector once found.
market connector returned unverifiable by design — no
free, authoritative, machine-queryable source; the named source (NAPHIA) is licensed and
must be human-attached.
unconfirmed here is a licensing gap in the connector surface, not a finding —
the underlying number is a purchasable, well-defined statistic. No chair had raised a
request against it (Market Access explicitly declined to re-bind it), so Front End raised
REQ-0015 What does the NAPHIA State of the Industry… (front-end → research) while opening this loop record.
unverifiable from market by design (no
free, authoritative, machine-queryable source), and the usual decomposition route
(procedures) is Medicare fee-for-service and structurally blind to animal procedures.
unconfirmed-is-a-gap-in-the-check case the protocol names. No request existed for any of
the three; Front End raised REQ-0016 What do VetCompass US / the Veterinary… (front-end → research) while opening this loop record.
unverifiable from adoption by design —
stakeholder-future claims with no free, authoritative source; the connector's own
instruction not to substitute a model's estimate of stakeholder behaviour was followed, and
nothing was fabricated in its place.
research request could
answer; both are named, buildable next steps outside this pipeline's connector surface
entirely, the same shape as Clinical's own bound conditions (claims 46/47) below.
literature-detail 34115409 returned found and the Verifier
re-read the record for device identification. **The abstract names no device, brand,
manufacturer, or form factor anywhere in its structured text.** That is a property of the
abstract, not of the study — the full text is where a methods section names a device, and
it was not retrieved.
conditional has a gap in it rather
than a finding under it. If it used a canister-free system, the closest evidence to this
candidate's exact site and form factor is negative, and Clinical has named that as one of
two findings that would move its verdict toward blocks.
trials against ClinicalTrials.gov for an animal
study with no prospective registration, and did not run recalls/maude against a joint
with no design record — declining to make a call that would come back empty and read like
an absence of evidence. Two of the five have a half the Verifier did settle by
inspection: claim 57unconfirmed's "no second source named anywhere in the file" is confirmed (the file
is silent), and claim 59unconfirmed's recall-history half is already verified at claim 37unconfirmed — 19 of 37
product-code-OMP recalls name a canister/connector/tubing defect, and the six 2014 Smith &
Nephew "Soft Port" recalls describe a sealing failure adjacent to a dressing connector.
Neither confirmed half is the load-bearing half.
research request could answer, and no request is raised
against them for the same reason IR-8 claims 23 raised none — a request nobody in this organisation
can fill is a ledger row for cover. Technology has already named the settling artifact: a
bench report showing a combined drape+interface assembly holding -80 mmHg on a furred,
articulating limb model through a simulated wear/chew/re-bandage cycle. Claims 46 and 47
are the artifact, written by Clinical as a pre-registered protocol, which is the most
useful form an unbuilt claim can take. What this review adds to IR-8 claims 23 is the sequence:
claim 51unconfirmed is the assembly test and it must come after the two component tests, not with
them, or a passing component masks a failing assembly; claim 59unconfirmed says the joint belongs in
the same bench report; and claim 57unconfirmed does not become answerable until the formulation behind
claim 51unconfirmed is chosen, so it is commissioned against that milestone rather than against a
document. Absorbing any of the five would mean deciding the engineering bet does not need
to be settled before somebody funds it.
regulation connector serves eCFR text, and the eCFR
versioner API it calls has no U.S. Code endpoint to call in the first place — so §§ 351/352
are not unattempted here, they are unreachable, and the same scope limit ("it does not
serve case law or enforcement practice") takes the second half of claim 50unconfirmed out of range
too. The file: hcpcs A6550 — a real human NPWT-dressing code used purely as a probe
of the code set's own scope — returned unconfirmed on a missing
data/hcpcs_level_ii.csv. What the Verifier did establish on claim 53unconfirmed is the more
interesting half: regulation 400.202 --title 42 returned verified, and Medicare's own
definitions section speaks throughout of an entitled individual and never uses the word
"human" or names an exclusion of animals. The Verifier declined to read "individual" as
"human being, not an animal" on eCFR text alone. That restraint is the right call and it is
why the claim is unconfirmed rather than verified.
data/hcpcs_level_ii.csv is a missing cache and
engine/scripts/fetch_data_file.py is the tool for one — the IR-5 claims 13 shape from idea-001's
record, where a missing file was named a job and nothing was raised. Its unretrievable
half is the honest residual and no commission touches it: per the connectors' own scope,
hcpcs/payment/coverage each test one named code and none can enumerate the
non-existence of a code for an entire category, so even a populated cache could never prove
a structural exclusion. A27 No HCPCS Level II code is therefore commissioned as far as it can be and stated as
permanently short of verified — which is a different thing from being wrong, and the
distinction belongs in the wrap rather than in a chair's confidence.
adoption, which returned unverifiable —
"asserts what clinicians, payers, or patients would do... needs primary research." The
routing is the finding. adoption is the right instrument for a stakeholder future, and
neither of these is one: an adjudication mechanism is a documented business process and
policy wording is a published document. What the routing actually records is that no
connector in this repo reaches private-insurer policy text at all, so the closest available
tool was one built for a different kind of claim, and its verdict understates what is
retrievable here.
adoption verdict is not a reason to stop asking. REQ-0042 Retrieve is that commission, front
end → research, raised 2026-09-17 against at least three major US pet insurers, asking for
quoted wording on both the adjudication basis and any categorical NPWT exclusion. It asks
for an insurer whose wording does not address the question to be reported as **silent
rather than as permissive**, which is the specific way this request would come back looking
more settled than it is. A negative return settles these claims as well as a positive one,
and the honest outcome then is not another commission.
unconfirmed means the check could
not reach the answer. Here the check reached it: the document is absent, which is closer to
a finding than to a gap, and what is commissioned is therefore the work that would make the
claim true rather than a lookup that would show it already is. REQ-0043 Write, as a document distinct from the… is that
commission, front end → technology, raised 2026-09-17. It goes to the chair rather than to
research because writing a design-input specification is not a retrieval — and it is raised
as a request rather than left as a note because Operations cannot price a subassembly
against a standard nobody has named, which makes one chair's undone work another chair's
blocked condition. It is also the cheapest item in this batch after REQ-0040 Retrieve the full text: naming IEC
60601-1, 60601-1-11 and 62133-2 as targets costs a document, not a study.
and claim 61unconfirmed` — that capital funds production-scale tooling
and a unit COGS supporting the $180–$320 price, not a pilot-volume build. `claim 52unconfirmed and claim 58unconfirmed` — the estimate excludes battery/electrical-
safety and biocompatibility qualification, and excludes ground-up bench and in-vivo
development spend for the drape chemistry and limb interface.
market returned unverifiable on claim 41unconfirmed with the same "no free, authoritative,
machine-queryable source" detail the other financial lines carry — it is a timeline and
capital-sufficiency projection with no filing behind it. On claims 52 and 58 the Verifier
did what it could and did it by inspection: re-reading claim 18unconfirmed's own text confirms it
names only dressing tooling, sterile packaging validation, and one or two prospective
clinical case series, with no line item for battery-safety testing, ISO 10993
biocompatibility, or ground-up material-science formulation. **So the textual half of both
exclusion claims is established and the cost-pricing half is not** — we know what claim 18unconfirmed
does not say; nobody has priced what it left out. The Verifier also notes claims 54 and 61
are the same claim in substance, bound independently by Operations (C2) and Commercial
(C9), which is corroboration between chairs rather than two facts.
US9061095B2 and the other
two) each returned unconfirmed, "No EPO OPS record found" — **a kind-code mismatch, not a
nonexistence finding**, and the connector's own documentation distinguishes the two. Re-run
with bare publication numbers, all three returned verified. Second, what they returned:
Wound dressing and method of use (filed 2011-04-21, naive term to 2031), *Negative
Pressure Wound Therapy Apparatuses and Methods for Using the Same* (filed 2018-02-15, to
2038), and Absorbent Negative Pressure Wound Therapy Dressing (filed 2021-08-16, to
2041). **All three exist, all three are live, and all three are titled squarely in this
candidate's subject matter.** What no connector can do is the claim chart itself — claim
scope construction and infringement opinions are reserved to a human-drafted FTO memo at
Stage 7 by phase2-spec.md §4, never rendered by any agent.
one-rule.md puts an FTO memo at Tier 3 and an agent
drafting one would be exactly the simulated Tier 3 decision no command here may make. So it
is commissioned to the boundary and stops there: the inputs are established, the chart is
not, and Legal & IP's conditional is correctly held rather than resolved either way.
No request is raised — the same reasoning as IR-11 claims 46, since no department in this
organisation can fill it. Two things this review does own. **The kind-code lesson is a job,
not a question**, and it generalises past this file: unconfirmed from a connector can mean
"wrong query shape" as easily as "no such record", and here the difference was three live
patents that a first pass read as absent — the same lesson idea-001's IR-1 claims 5 and 6 came back unconfirmed recorded about
an address that resolved to the wrong policy. And the finding travels ahead of the memo:
a live unexpired patent family reading on canister-free NPWT dressings is worth Legal & IP
knowing now, not at Stage 7, which is why claim 64unconfirmed's own note flags it for counsel rather
than parking it.
reshaping: the disposable pump can hold the setpoint at the dressing for the
labelled course inside a disposable's cost class).
unconfirmed for want of an instrument. This is the case the
protocol routes to commission, and nothing has been refuted. **The settling artifact is the
same for both, and it is the one B7 A single-use disposable pump can hold the… already names.** It is an instrumented bench rig on a
limb model that logs pressure at the dressing port and pump ON-time against a calibrated
leak, plus fault injection with the firmware deliberately disabled. In-vivo duty logging
can then ride on the claim-46 study as a firmware counter. Nobody in this organisation can
run that, so no request is raised for the bench itself, on IR-8 claims 23's and IR-11 claims 46's precedent. The
dependency is stated instead: **it needs a built PS-1, which needs REQ-0066 The pump subassembly now has a named…'s quote, and
that quote rests on claim 65unconfirmed's number.** That loop is real. The honest way out of it is to
quote REQ-0066 The pump subassembly now has a named… at both the 7% and the 20% duty pack sizes rather than at one. One piece of
claim 65unconfirmed can be moved from inside the organisation, and it is commissioned:
REQ-0148 Extending manifest row… (front-end → research). It asks the canine and equine NPWT case series already
indexed for this domain whether any single-use pump was replaced before its labelled life,
and why. It also asks the PICO-class analog's own IFU (instructions for use) for its labelled life, cells and leak
alarm condition. That bounds claim 65unconfirmed and does not settle it, and the request says so.
Its phrase "on primary AA cells" describes PS-1, not a known fact about the analog. The
analog's cells are one of the things it asks for. claim 66unconfirmed has no such proxy. A pressure
control band and a single-fault limit belong to this design alone, and no published analog
says anything about a pump that does not exist.
refuted because no connector returned
refuted. It left the claim's "no exemption available" assertion unestablished, with at
least two open routes.
costly) cites it among its seventeen.
unconfirmed, and settleable inside this organisation by the chair whose
field it is. Commissioned as REQ-0149 Claim 67 (front-end → regulatory), which asks three
things. Is a veterinarian-dispensed home-use pump a "specialized medical digital device"
under 15.103(e), and has FCC said so anywhere, by document identifier? Does any other
15.103 paragraph reach a battery-only design? Does any HMR provision outside 173.185 attach
to alkaline cells in equipment? It goes to Regulatory rather than back to Technology,
because a chair does not settle its own condition, and the chair itself named the 15.103
half as the part it is least sure of. This was not treated as a refutation to absorb,
although the eCFR text leans against the claim's wording. The part that leans against is a
paragraph that needs a human ruling, not a finding. And A41 UN Manual of Tests and Criteria Part III… reads correctly either way,
because the answer moves a line in REQ-0066 The pump subassembly now has a named…'s quote. Operations can quote Part 15 as a
separable line so that the answer drops in without re-quoting. REQ-0065 Over what ambient temperature range (equine unheated
housing, and therefore lithium or alkaline) decides whether the UN 38.3 half applies to the
product at all. REQ-0149 Claim 67 does not duplicate it.
unconfirmed for want of access, not on contrary evidence, and the
cheapest settling source is public. The chair itself says the IEC Webstore abstracts carry
the scope clauses. Commissioned as REQ-0150 Quote verbatim (front-end → research: the verbatim scope
clauses of IEC 62133-2 and IEC 60086-4) and REQ-0151 Quote verbatim (front-end → research: IEC
60601-1's Clause 3 PATIENT definition and note, its Clause 1 scope sentence, and 60601-1-11's
scope). Both tell the researcher to stop and say so if only a purchase reaches the text. If
that happens, the settling artifact becomes a human buying two standards, which is cheap and
outside this organisation. The ordering is the part to act on. **REQ-0150 Quote verbatim should land before
Operations quotes REQ-0066 The pump subassembly now has a named…**, because the quote names IEC 60086-4 and claim 68unconfirmed is the reason
it does. REQ-0151 Quote verbatim should land before Regulatory answers REQ-0067 If this pump is designed and tested to IEC…, because that request
assumes the standard is in scope. The two claims are grouped because the failure reason is
identical. They stay two requests because each names a different statement it would settle.
The subset of claims that are load-bearing, each with who depends on it and what breaks if it is false. Rows arrive two ways — the front end writes one, or a chair binds a condition to a claim, which is the definition of load-bearing.
If it is false: If refuted (the foundational Wake Forest patent US5636643 is not in fact expired): a live enforceable NPWT patent exists that must be checked against this device's mechanism before Legal & IP can move off abstains, and REQ-0006 What US patents's landscape search has to add it as a candidate blocking patent rather than treating the foundational estate as closed. While it stays unconfirmed on a missing-credential basis, Factor 4 (FTO/IP) cannot move off blank from this line, and Legal's abstains cannot resolve even its cheapest half.
Depends on it: Legal & IP
If it is false: Same mechanism as A1 US Patent 5,636,643, plus a distinct second failure mode the file already flags: 5,645,081 may be the wrong Wake Forest family member entirely. If a human check shows it is not a Wake Forest NPWT patent, the foundational-estate half of the FTO opinion has no correct second citation and REQ-0006 What US patents has to establish the right number from scratch.
Depends on it: Legal & IP
If it is false: Legal's own words: this "is the one that actually decides the question." If a landscape search finds a live Smith & Nephew PICO-family patent reading on canister-free/superabsorbent NPWT or dressing-interface chemistry, the "fast-follower has no regulatory delay" framing (claim 17unconfirmed) inverts into an FTO block — Route A (standalone sale) and Route B (licensing the drape/interface module) both lose the product they would sell or license.
Depends on it: Legal & IP, Commercial (REQ-0009 Does a prior-art/FTO search establish that…)
If it is false: Market Access's own text: even if C2/C3 resolve favorably, a sub-5% penetration rate bounds how much of the caseload the pet-insurance "offset" leg could ever reach. A materially different true figure resizes the population that needs the offset to afford treatment, feeding directly into Commercial's TAM (claims 13-15) and owner-willingness-to-pay (claim 21unconfirmed).
Depends on it: Market Access (unbound 4th condition), Commercial (context)
If it is false: Commercial's own midpoint (~55k qualifying canine cases/yr) is a Generator estimate with no primary source. If the true caseload sits at or below the 30k floor, the revenue pool behind Routes A/C/D falls below a size worth building tooling and distribution for — the Scorer's note calls this "the hardest to close" component and possibly "permanently unconfirmable inside this pipeline."
Depends on it: Commercial (C1)
If it is false: This price sets both the revenue-per-unit assumption and the ceiling Operations's C2/C6 and Commercial's C7 gross-margin conditions are tested against. If the achievable price is materially lower than $180-$320 — plausible if off-label PICO (claim 25unconfirmed) is cheaper — the COGS-plus-distributor-margin math (claim 27unconfirmed) may not close at any production volume, independent of whether the device can be built at all.
Depends on it: Commercial (C2)
If it is false: The claim's own text concedes the 20-30% obtainable-share figure is "a modeling choice rather than a fact... an argument, not a lookup." If a survey or directory count shows actual specialty/referral concentration is materially lower, obtainable revenue in Routes A/C/D shrinks proportionally even with caseload (A5 TAM component 1) and price (A6 TAM component 2) both holding.
Depends on it: Commercial (C3)
If it is false: "Patentable" is a prospective legal judgment; Legal's own corroborating check found ~10 new product-code-OMP clearances a year with ongoing drape-specific filing activity from incumbents through 2024. If a prior-art search shows the drape/interface space is already claimed or too crowded to file around, there is nothing to defend in Route A and nothing to license in Route B — Factor 5 (Moat) has no path off blank either way.
Depends on it: Legal & IP (C4), Commercial (REQ-0009 Does a prior-art/FTO search establish that…, Route B)
If it is false: This is the file's own strongest scored factor (Factor 7, draft 4/5) and the candidate's stated reason for being interesting at all — "no premarket submission, no IDE/IND-equivalent gate... first revenue plausibly at low-single-digit millions." Operations's own read is that the figure is "an under-scoped estimate." If it is confirmed under-scoped, that advantage shrinks or disappears.
Depends on it: Commercial (C8), Operations & NPI (context to C1/C2)
If it is false: Commercial's own "What would change my mind": a negative survey answer here "alone is enough to kill Routes A and C in the existing business case without spending anything further on sizing." If vets will not switch from off-label human PICO, the standalone-hardware business has no customer at any price, caseload, or margin.
Depends on it: Commercial (C5)
If it is false: If owners will not pay several hundred dollars out of pocket on top of the surgical bill, the cash-pay mechanism Market Access's entire verdict rests on has no payer at any price point Commercial has modeled, independent of caseload or margin.
Depends on it: Commercial (C4)
If it is false: If a technician cannot reliably achieve a working seal without specialist training or adhesive spray, the labor/training cost this candidate's model assumes (technician-applied, home-dispensed) is understated, and the device may need a level of in-clinic supervision that undercuts the post-discharge, at-home commercial model it is built around.
Depends on it: Operations & NPI (C8)
If it is false: If no major US veterinary distributor will carry an unbuilt SKU, Route A has no channel into the specialty/referral and equine practices the TAM assumes are reachable, regardless of demand or price.
Depends on it: Commercial (C6)
If it is false: Both chairs bind this independently. Commercial's own business case states the whole Route A sales motion "is killed" if gross margin does not survive dressing COGS and the distributor's own cut — an explicit kill condition already written into the commercial file, not a soft risk.
Depends on it: Operations & NPI (C6), Commercial (C7)
If it is false: Both chairs bind this independently; Technology and Clinical both separately name this as the file's highest-value verification target. The closest existing analog (PICO) is already documented "problematic in maintaining a vacuum" on an easier, clipped, non-weight-bearing surface, and separately unable to complete an open-wound seal study in horses "despite the use of many adjunctive adhesives" (PMID 30841889). If this candidate's drape cannot hold seal at -80 mmHg for 72 hours, the mechanism and the moat fail at the same point.
Depends on it: Technology & R&D (C1), Operations & NPI (C3)
If it is false: Both chairs bind this independently. The closest species/procedure analog already shows this exact failure mode: a dog receiving NPWT over a skin graft (claim 38unconfirmed) had a bandage complication after NPWT cessation that caused partial graft loss.
Depends on it: Technology & R&D (C2), Operations & NPI (C4)
If it is false: Technology names this "the single highest-value item to watch" of its four feasibility claims. The AJVR analog (claim 9unconfirmed) already reports this exact failure mode — "self-limiting skin irritation... hampering attainment of negative pressure" — on a different adhesive/foam interface; if it recurs here, the device cannot hold therapeutic pressure at home, defeating the whole post-discharge value proposition.
Depends on it: Technology & R&D (C3)
If it is false: If sterile packaging and dressing tooling cannot be validated to ISO 11607 absent premarket review, the "no IND/IDE-equivalent required" cost advantage (claim 18unconfirmed/Factor 7) is real on the regulatory side and blocked on the manufacturing side — the device cannot ship regardless of what the market or clinical evidence says.
Depends on it: Operations & NPI (C5)
If it is false: If first revenue is not reachable within a calendar consistent with the low-single-digit-millions capital figure, Factor 7's "cheap and fast" thesis loses the "fast" half even if the dollar figure holds.
Depends on it: Commercial (C8, calendar half)
If it is false: Clinical's own bar for moving off conditional toward supports; Technology names the same study as the cheapest artifact that would move its own C1/C2/C4 together. If the interface fails to avoid the seal-failure mode already documented for PICO in these species, Clinical states this is one of two findings that "would move this verdict toward blocks."
Depends on it: Clinical & Scientific (C1), Technology & R&D (adopts as its own basis)
If it is false: The only controlled comparison that already exists at this candidate's exact site (equine distal limb, claim 20unconfirmed) found NPWT worse than calcium alginate early and no long-term advantage. If a prospective study against this candidate's own device does not show a favorable effect versus standard of care, Clinical has no basis to move off conditional, and per Clinical's pivot note this must resolve favorably in horses specifically before the position can move past conditional for any indication keeping the equine segment.
Depends on it: Clinical & Scientific (C2)
If it is false: The CFR reads (807.81/807.20/807.65) have already returned verified once, quoted inside claim 1unconfirmed's notes, but never on their own claim line. If this does not verify cleanly when run cold on its own line, Regulatory's stated "cheapest move available today" toward supports fails, and the premarket-notification conclusion stays anchored only inside claim 1unconfirmed's attribution notes, which can never verify by design.
Depends on it: Regulatory (C1)
If it is false: Same mechanism as A22 21 CFR 807.81 for 814.1(a)/PMA scope. If it does not verify on its own line, the PMA-exemption conclusion has the same unresolved anchoring problem.
Depends on it: Regulatory (C2)
If it is false: Regulatory is explicit: "no premarket review" is not "no regulatory exposure." If post-market misbranding/adulteration authority is confirmed to reach this device's therapeutic-effect language ("reduce edema, promote granulation, and stabilize skin grafts"), that labeling becomes a live enforcement surface — Regulatory warns this must not be read in anyone's head as "label whatever the mechanism plausibly does." Commercial's C8 (claim 18unconfirmed) also inherits this indirectly via claim 1unconfirmed/3.
Depends on it: Regulatory (C3)
If it is false: Technology names this "the integration-risk condition": the drape and the chew-resistant shell have opposing material-property pulls. If the combined assembly fails a bench test even when each component passes alone, C1 and C2 passing independently would be misleading — a working drape and a working shell do not guarantee a working device.
Depends on it: Technology & R&D (C4)
If it is false: If battery/electrical-safety qualification and drape biocompatibility/skin-irritation qualification are not already priced into claim 18unconfirmed, Operations states this is "additional NPI cost and schedule items beyond the two named in claim 18unconfirmed" — a confirmed gap directly under-scopes the capital figure Commercial's C8 and Factor 7 both depend on.
Depends on it: Operations & NPI (C1)
If it is false: This is Market Access's structural premise for the whole reimbursement-side verdict — no HCPCS/CPT/Medicare/Medicaid mechanism can ever apply to an exclusively-veterinary device. If a human read of 42 U.S.C. § 1395c and 42 CFR 400.202 against the HCPCS code-request process shows this is not in fact categorical, Market Access's "revenue is cash-pay, full stop" framing has to be redone, potentially opening a coding/coverage path the commercial model does not contemplate.
Depends on it: Market Access (C1)
If it is false: If the capital estimate funds only pilot-volume tooling that would need re-tooling before any commercial-volume order could be filled, "low-single-digit-millions to first revenue" is not the same figure as "low-single-digit-millions to sustainable $180-$320 unit economics" — Operations's own human check requires a second cost-of-goods build-up at 10x volume before treating claim 18unconfirmed as a plan.
Depends on it: Operations & NPI (C2)
If it is false: Market Access states this is what converts "optionally offset by pet insurance" from "a hopeful clause" into "a bounded number." If pet insurers in fact adjudicate by matching a procedure code (contrary to this condition), the absence of a CMS code categorically blocks the insurance-offset leg rather than merely bounding it.
Depends on it: Market Access (C2)
If it is false: If a major US pet insurer's policy language does categorically exclude NPWT or wound-care adjunct devices, the insurance-offset leg is foreclosed regardless of penetration rate or adjudication mechanism (claims 12, 55) — Market Access names this as one of its two load-bearing unknowns, alongside C2.
Depends on it: Market Access (C3)
If it is false: Operations names this "a concentration risk worth naming at concept stage." If the drape depends on a single adhesive/coating formulation and a single qualified converter with no second source anywhere in the file, a single supplier disruption stops the entire product's supply chain — a different and more fragile risk than the cost questions in C1/C2/C6.
Depends on it: Operations & NPI (C7)
If it is false: If claim 18unconfirmed's capital estimate excludes ground-up bench/in-vivo development spend for the drape and interface (both unbuilt, both the file's own stated moat), the "cheap and fast" Factor 7 thesis is missing an entire cost bucket upstream of the tooling and packaging validation it does name — compounds with A9 Capital intensity (claim 18unconfirmed) and A26 The capital-intensity estimate for reaching… (claim 52unconfirmed).
Depends on it: Operations & NPI (C9)
If it is false: Raised answering REQ-0008 Does the candidate's proposed…: the closest canister-free analog (Smith & Nephew PICO) has its own recall history naming a sealing/port failure adjacent to a dressing connector. If this candidate's pump-to-dressing joint repeats that failure mode, the device fails at the mechanical connector even if the drape's adhesive chemistry independently holds seal — a second, independent failure point beyond A15 A fur-compatible adhesive drape can hold a…-A17 Adhesive and drape contact on furred….
Depends on it: Technology & R&D (C5)
If it is false: Raised answering REQ-0014 Does a design-input specification exist for…: if no design-input spec (battery chemistry/capacity, electrical-safety standard, duty cycle, pressure-control tolerance) exists for the pump subassembly independent of the dressing/drape system, the pump stays an unspecified commodity item and Operations's capital estimate (claim 18unconfirmed/52) cannot be priced against a named standard.
Depends on it: Technology & R&D (C6)
If it is false: Raised answering REQ-0013 Is the $180-$320 net selling price per unit: Commercial's own reading is that claim 18unconfirmed's capital estimate funds pilot-volume tooling only, not the commercial-scale tooling ordinarily needed to reach the $180-$320 unit economics claim 14unconfirmed assumes — a second, larger capital raise may be needed before the price claim is reachable at all, independent of what REQ-0018 What does an itemized contract-manufacturer…'s COGS benchmarking found.
Depends on it: Commercial (C9)
If it is false: Raised answering REQ-0011 Does a full-text read of the AJVR 2022 study: no single study in the file yet tests both this candidate's site (distal limb, claim 20unconfirmed) and its form factor (canister-free, claim 9unconfirmed) at once. If the equine study's device is confirmed conventional-canistered rather than canister-free, claim 20unconfirmed's unfavorable finding does not yet establish that the canister-free form factor underperforms at this site — a gap in, not a resolution of, Clinical's conditional verdict.
Depends on it: Clinical & Scientific (C4)
If it is false: Raised answering REQ-0010 Does FDA CPG Sec. 655.100: the promoted CPG/FD&C Act report found 21 U.S.C. §§ 351/352 apply their misbranding/adulteration grounds to "a drug or device" with no human-use qualifier, unlike the premarket sections' express human-use limitation. If a human read of the full statutory text and FDA's enforcement posture confirms this reading, post-market labeling exposure over the candidate's therapeutic-effect language ("reduce edema, promote granulation, stabilize skin grafts") is live regardless of the confirmed premarket exemption — bears on Commercial's cash-pay marketing latitude (claim 18unconfirmed/Factor 7).
Depends on it: Regulatory (C4)
If it is false: Raised as the actual settling artifact for A1 US Patent 5,636,643-A3 FTO risk concentrates not in the expired…: the promoted patent-landscape report found three live Smith & Nephew canister-free NPWT patents (US9,061,095 B2 Veterinary surgeons switch from the human…, US11,395,870 B2 Veterinary surgeons switch from the human…, US12,453,658 B2 Veterinary surgeons switch from the human…) whose retrieved independent claims recite no species or human-only limitation. This is adverse, not yet dispositive — a public keyword search is not a claim-chart opinion. If a professional claim-chart comparison finds literal or doctrine-of-equivalents infringement with no available design-around, Route A (standalone sale) and Route B (licensing) both lose the product they would sell or license, the exact failure mode A3 FTO risk concentrates not in the expired… named.
Depends on it: Legal & IP (C5)
If it is false: Raised answering REQ-0043 Write, as a document distinct from the…: the pump's 6 Wh energy budget and 7-day therapy duration are both wrong. At a leak-driven 20% duty the pack yields ~2.6 days rather than 7, the cell count rises, and the BOM Operations is about to price under REQ-0066 The pump subassembly now has a named… changes before it is quoted. claim 9unconfirmed is direct reason to expect the in-service figure is worse than the design figure — a PICO-class device on an easier, clipped surface was "feasible but problematic in maintaining a vacuum, requiring frequent revisions of the dressing".
Depends on it: Technology & R&D (C7); Operations & NPI downstream via A26 The capital-intensity estimate for reaching…/A28 The low-single-digit-millions capital…
If it is false: Raised answering REQ-0043 Write, as a document distinct from the…: the device cannot deliver a controlled dose. Either it under-delivers — pressure measured at the pump rather than at the dressing port is how an "80 mmHg" device delivers 60 — or, absent the independent non-firmware hardware limit at -110 mmHg, a firmware fault can drive an ischemia or graft-shear over-pressure on a limb whose patient cannot report it.
Depends on it: Technology & R&D (C8)
If it is false: Raised answering REQ-0043 Write, as a document distinct from the…: the mandatory/voluntary split at the heart of the PS-1 pump specification is wrong, in one of two expensive directions — an unqualified regime appears late (a lithium product that cannot be air-shipped, or an FCC authorisation nobody budgeted), or money is spent qualifying against a regime that never applied. The chair records the 47 CFR 15.103 exemption half as the part it is least sure of.
Depends on it: Technology & R&D (C9); Operations & NPI (cost of goods, logistics)
If it is false: Raised answering REQ-0043 Write, as a document distinct from the…: the subassembly gets priced and quoted against IEC 62133-2 — a standard scoped to secondary (rechargeable) cells, which no test house can apply to a single-use disposable carrying primary cells. IEC 60086-4 is the primary-lithium standard. This is precisely the "priced against an unspecified commodity item" failure REQ-0043 Write, as a document distinct from the… was raised to prevent, returning in a new form.
Depends on it: Technology & R&D (C10); Operations & NPI (REQ-0066 The pump subassembly now has a named… pricing)
If it is false: Raised answering REQ-0043 Write, as a document distinct from the…: the rationale for naming the IEC 60601 stack collapses. The chair's position is that 60601-1 is in scope by the standard's own terms — its definition of PATIENT is a "living being (person or animal)" — so naming it is voluntary for want of an obligation, not for want of scope. If that reading is wrong and 60601-1 really is human-only by scope, it cannot serve as a contract acceptance standard or a product-liability benchmark for this device, and PS-1's voluntary column needs rebuilding from a different premise.
Depends on it: Technology & R&D (C11); Regulatory via REQ-0067 If this pump is designed and tested to IEC…
Any department may ask any other what it cannot answer itself. The answer must name an artifact that exists — a research report, a position, a dossier — never a summary.
| Request | From → to | Question | State |
|---|---|---|---|
| REQ-0004 | regulatory → research | What does FDA Compliance Policy Guide Sec. 655.100 (CPG 7125.35, "Devices Used in Animals") actually state about premarket notification/approval exemption for animal-only devices, read in full from the FDA Compliance Policy Guides manual? | answered |
| REQ-0005 | regulatory → research | What do FD&C Act Secs. 501 (adulteration) and 502 (misbranding), read in full, establish about FDA's post-market enforcement authority over labeling and efficacy claims for a device with no premarket review, and does FDA's stated enforcement posture (per CPG… | answered |
| REQ-0006 | legal-ip → research | What US patents, held by Smith & Nephew (or successor assignees T.J. Smith & Nephew, BlueSky Medical, Solventum/3M) or any other party, are live and claim canister-free/superabsorbent single-use NPWT or dressing-interface/adhesive-drape chemistry in CPC… | answered |
| REQ-0007 | legal-ip → research | Is there available (unclaimed) patent scope for a fur-compatible adhesive drape chemistry and a chew/bandage-resistant limb-conforming NPWT interface layer for canine/equine distal-limb use — i.e., does a prior-art search on animal-skin-compatible adhesive… | answered |
| REQ-0008 | clinical → technology | Does the candidate's proposed fur-compatible adhesive drape and limb-conforming interface design specifically address the seal/adhesion failure mode already documented for the closest existing canister-free analog (PICO) -- reported 'problematic in… | answered |
| REQ-0009 | commercial → legal-ip | Does a prior-art/FTO search establish that the fur-compatible adhesive-drape chemistry and limb-conforming interface (claim 16unconfirmed) have available, patentable claim scope, and that the live Smith & Nephew PICO canister-free/superabsorbent and dressing-interface… | answered |
| REQ-0010 | commercial → regulatory | Does FDA CPG Sec. 655.100, read in full, establish that this animal-only device faces no premarket notification or premarket approval (claim 1unconfirmed), and does FDA's post-market misbranding/adulteration authority over labeling and claims (claim 3unconfirmed) impose any… | answered |
| REQ-0011 | commercial → clinical | Does a full-text read of the AJVR 2022 study (PMID 35973001, claim 9unconfirmed) and the Equine Veterinary Journal 2022 distal-limb study (PMID 34115409, claim 20unconfirmed) establish that canister-free single-use NPWT underperforms conventional care at or near this candidate's… | answered |
| REQ-0012 | technology → operations-npi | Does the capital estimate in claim 18unconfirmed (first revenue achievable for low-single-digit millions, dominated by dressing tooling, sterile packaging validation, and one or two prospective clinical case series) include bench and in-vivo development/validation spend… | answered |
| REQ-0013 | operations-npi → commercial | Is the $180-$320 net selling price per unit (claim 14unconfirmed) and the capital-intensity estimate for reaching first revenue (claim 18unconfirmed) quoted at commensurate production volumes -- does the capital that funds first revenue also fund tooling at the scale that would… | answered |
| REQ-0014 | operations-npi → technology | Does a design-input specification exist for the disposable battery-powered pump subassembly (battery chemistry/capacity, target electrical-safety standard, motor/pump duty cycle, negative-pressure control tolerance) independent of the dressing/drape system… | answered |
| REQ-0015 | front-end → research | What does the NAPHIA State of the Industry Report (or an equivalent licensed source) establish about US pet insurance penetration among owned dogs, and does it corroborate the under-5% estimate the candidate file carries? | answered |
| REQ-0016 | front-end → research | What do VetCompass US / the Veterinary Medical Database / Banfield-Mars State of Pet Health caseload data, published PICO US list/contract pricing cross-referenced against a veterinary distributor price file (Covetrus, Patterson Veterinary), and ACVS/AAEP… | answered |
| REQ-0017 | front-end → research | Based on direct outreach or a comparable newly-listed veterinary device SKU's terms, would at least one major US veterinary distributor (Covetrus, Patterson Veterinary, or Midwest Veterinary Supply) list and carry a veterinary-labeled, canister-free NPWT SKU? | answered |
| REQ-0018 | front-end → research | What does an itemized contract-manufacturer bill-of-materials / cost-of-goods estimate for the pump, battery, drape/adhesive and dressing, plus a distributor margin schedule (Covetrus, Patterson Veterinary), establish about whether gross margin survives at… | answered |
| REQ-0040 | front-end → research | Retrieve the full text (not the abstract) of PMID 34115409, Equine Veterinary Journal 2022, and report which NPWT system the study used: manufacturer, product name, and whether it is a canister-free single-use device or a conventional canistered pump. The… | answered |
| REQ-0041 | front-end → research | Retrieve, by citation, the current text of 21 U.S.C. 351 and 21 U.S.C. 352 from a primary source (uscode.house.gov or govinfo.gov), and report verbatim whether their introductory grounds apply to 'a drug or device' with no human-use qualifier, in contrast to… | answered |
| REQ-0042 | front-end → research | Retrieve, by policy document, the current published policy wording of at least three major US pet insurers (e.g. Trupanion, Nationwide, Healthy Paws, ASPCA/Crum & Forster) and report two things per insurer, quoting the wording: (a) whether indemnity claims… | answered |
| REQ-0043 | front-end → technology | Write, as a document distinct from the dressing/drape system's own design inputs, a design-input specification for the disposable battery-powered pump subassembly: battery chemistry and capacity, the named target electrical-safety standard (the obvious… | answered |
| REQ-0065 | technology → clinical | Over what ambient temperature range, and for what continuous unsupervised wear duration, is this pump expected to run in the EQUINE post-discharge setting (unheated barn or stall, overnight, winter) as against the canine at-home setting? The pump design-input… | open |
| REQ-0066 | technology → operations-npi | The pump subassembly now has a named standards set and a named BOM class -- see 'Design-input specification -- pump subassembly PS-1' in knowledge-base/positions/idea-002-technology.md. The mandatory-by-some-route items are UN 38.3 (lithium variant only) and… | open |
| REQ-0067 | technology → regulatory | If this pump is designed and tested to IEC 60601-1 and IEC 60601-1-11 as a voluntary target, does STATING that conformity on an animal-only label or in animal-only sales material create a labeling representation FDA's post-market misbranding authority could… | open |
| REQ-0148 | front-end → research | Extending manifest row canine-equine-distal-limb-wounds.care-pathway.npwt-devices-consumed-per-treated-animal (same case series, same sources): for each published canine or equine NPWT case series using a portable single-use canister-free pump (at minimum… | open |
| REQ-0149 | front-end → regulatory | claim 67unconfirmed (Technology C9) came back unconfirmed on 2026-09-29, and the Verifier's eCFR reads split it. 49 CFR 173.185(a)(1) requires UN 38.3 for lithium cells, which supports the lithium half. 47 CFR 15.101 allows Supplier's Declaration of Conformity for Class… | open |
| REQ-0150 | front-end → research | Quote verbatim, with edition and the publisher's page URL or document identifier, the Scope clause (Clause 1) of IEC 62133-2 and of IEC 60086-4, current editions, from the IEC Webstore abstract or free preview pages. Report specifically (a) whether IEC… | open |
| REQ-0151 | front-end → research | Quote verbatim, with edition and the source's identifier, IEC 60601-1's Clause 3 definition of PATIENT and any note to it on non-human patients, and IEC 60601-1-11's Clause 1 scope statement. Use a primary source: the IEC Webstore free preview, IEC… | open |
python3 engine/scripts/check_loop.py --candidate idea-002 --open
Nothing on this page is a recommendation, and no verdict here is a decision. This is a compilation of what the loop record, the position files and the request ledger say. Shortlist review and every decision past it are human-only.
_shared/plain-language.md